Endovascular thrombectomy versus medical treatment for large vessel occlusion stroke with mild symptoms: A meta-analysis.
Yong-Jie XiongJia-Ming GongYi-Chi ZhangXin-Ling ZhaoSha-Bei XuDeng-Ji PanWen-Sheng QuDai-Shi TianPublished in: PloS one (2018)
It remains controversial as to whether mechanical thrombectomy (MT) is safer and more beneficial in patients with large vessel occlusion stroke (LVOS) presenting with a National Institutes of Health Stroke Scale score ≤ 8. We therefore conducted a meta-analysis of the published data.We searched PubMed and Embase and pooled relevant data in the meta-analyses using fixed effects models. Only studies that directly compared best medical therapy alone (BMT) with MT were included. We used odds ratios to analyze the associations between MT and 90-day functional outcome (evaluated using the modified Rankin Scale (mRS)), mortality, and rates of symptomatic intracerebral hemorrhage (sICH) in patients with LVOS and minor symptoms. Five studies including a total of 581 patients met our inclusion criteria. A significant difference was found that the patients treated with MT were associated with improved 90-day mRS score (OR, 1.68; 95% CI, 1.08-2.61) compared with BMT group. There was no difference in 90-day mortality between the two groups. However, sICH occurred more frequently in the MT group than the BMT group (OR, 3.89; 95% CI, 1.83-8.27). Patients with LVOS with minor or mild symptoms who underwent primary thrombectomy had a significantly improved 90-day mRS score compared to those who received BMT alone. Meanwhile, the risk of sICH was higher in the MT group than that in BMT group. Future randomized clinical controlled trials evaluating the role of endovascular reperfusion for LVOS with minimal symptoms are warranted.
Keyphrases
- atrial fibrillation
- healthcare
- meta analyses
- systematic review
- end stage renal disease
- cerebral ischemia
- sleep quality
- cardiovascular events
- acute ischemic stroke
- electronic health record
- public health
- chronic kidney disease
- newly diagnosed
- brain injury
- clinical trial
- heart failure
- open label
- stem cells
- randomized controlled trial
- acute myocardial infarction
- ejection fraction
- bone marrow
- double blind
- quality improvement
- prognostic factors
- risk assessment
- big data
- machine learning
- tyrosine kinase
- acute coronary syndrome
- cardiovascular disease
- climate change
- left ventricular
- physical activity
- mesenchymal stem cells
- health information
- deep learning
- aortic dissection
- phase ii
- replacement therapy
- case control